Léonard Bezinge

Léonard Bezinge

Auto-generated profile, based on publicly available information

Léonard Bezinge

BÜHLMANN Laboratories AG Schönenbuch Switzerland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2020 in Nature
Verified
Journal Article
Closed access
PDF file
BMBenjamin S. Miller
Benjamin S. Miller
LBLéonard Bezinge
Léonard Bezinge
HGHarriet D. Gliddon
Harriet D. Gliddon
DHDa Huang
Da Huang
GDGavin Dold
Gavin Dold
RMRachel McKendry
Rachel McKendry

16 May 2018 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
LBLeonard Bezinge
Leonard Bezinge
RMRichard M. Maceiczyk
Richard M. Maceiczyk
ILIoannis Lignos
Ioannis Lignos
MKMaksym V. Kovalenko
Maksym V. Kovalenko
ADAndrew Demello
Andrew Demello

8 November 2019 in Molecular Systems Design & Engineering
Verified
Journal Article
Open access
PDF file
LBLéonard Bezinge
Léonard Bezinge
ASAkkapol Suea-Ngam
Akkapol Suea-Ngam
ADAndrew Demello
Andrew Demello
CSChih-Jen Shih
Chih-Jen Shih
With the increasing importance of personalized medicine and genomics, biosensors have received considerable attention in various fields, including clinical diagnostics, food inspection and environmental monitoring. In particular, advances in electrochemical biosensing technologies for clinical diagnostics pave the way for ultrasensitive detection of nucleic acid sequences using miniaturized and low-cost devices suitable for point-of-use applications. This account reviews three major amplification strategies utilizing nanomaterials as (i) ‘nanocatalysts’ in electrocatalysis, (ii) redox active reporters (‘nanoreporters’) and (iii) cargos for redox markers (‘nanocarriers’). In addition, and motivated by the need for reproducible and robust sensing, the integration of biosensors with microfluidic tools, including paper-based devices, are also covered.

25 August 2020 in ACS Sensors
Verified
Journal Article
Closed access
ASAkkapol Suea-Ngam
Akkapol Suea-Ngam
LBLéonard Bezinge
Léonard Bezinge
BMBogdan Mateescu
Bogdan Mateescu
PHPhilip Howes
Philip Howes
ADAndrew Demello
Andrew Demello
DRDaniel A. Richards
Daniel A. Richards

27 May 2024 in Small
Verified
Journal Article
Open access
LBLéonard Bezinge
Léonard Bezinge
CSChih‐Jen Shih
Chih‐Jen Shih
DRDaniel A. Richards
Daniel A. Richards
ADAndrew Demello
Andrew Demello
Electrochemical paper‐based microfluidics has attracted much attention due to the promise of transforming point‐of‐care diagnostics by facilitating quantitative analysis with low‐cost and portable analyzers. Such devices harness capillary flow to transport samples and reagents, enabling bioassays to be executed passively. Despite exciting demonstrations of capillary‐driven electrochemical tests, conventional methods for fabricating electrodes on paper impede capillary flow, limit fluidic pathways, and constrain accessible device architectures. This account reviews recent developments in paper‐based electroanalytical devices and offers perspective by revisiting key milestones in lateral flow tests and paper‐based microfluidics engineering. The study highlights the benefits associated with electrochemical sensing and discusses how the detection modality can be leveraged to unlock novel functionalities. Particular focus is given to electrofluidic platforms that embed electrodes into paper for enhanced biosensing applications. Together, these innovations pave the way for diagnostic technologies that offer portability, quantitative analysis, and seamless integration with digital healthcare, all without compromising the simplicity of commercially available rapid diagnostic tests.

12 June 2024 in Analytical Chemistry
Verified
Journal Article
Open access
JLJake M. Lesinski
Jake M. Lesinski
TMThomas Moragues
Thomas Moragues
PMPrerit Mathur
Prerit Mathur
YSYang Shen
Yang Shen
CPCarolina Paganini
Carolina Paganini
DRDaniel A. Richards
Daniel A. Richards
Due to their ability to selectively target pathogen-specific nucleic acids, CRISPR-Cas systems are increasingly being employed as diagnostic tools. "One-pot" assays that combine nucleic acid amplification and CRISPR-Cas systems (NAAT-CRISPR-Cas) in a single step have emerged as one of the most popular CRISPR-Cas biosensing formats. However, operational simplicity comes at a cost, with one-pot assays typically being less sensitive than corresponding two-step NAAT-CRISPR-Cas assays and often failing to detect targets at low concentrations. It is thought that these performance reductions result from the competition between the two enzymatic processes driving the assay, namely, Cas-mediated cis-cleavage and polymerase-mediated amplification of the target DNA. Herein, we describe a novel one-pot RPA-Cas12a assay that circumvents this issue by leveraging in situ complexation of the target-specific sgRNA and Cas12a to purposefully limit the concentration of active Cas12a during the early stages of the assay. Using a clinically relevant assay against a DNA target for HPV-16, we show how this in situ format reduces competition between target cleavage and amplification and engenders significant improvements in detection limit when compared to the traditional one-pot assay format, even in patient-derived samples. Finally, to gain further insight into the assay, we use experimental data to formulate a mechanistic model describing the competition between the Cas enzyme and nucleic acid amplification. These findings suggest that purposefully limiting cis-cleavage rates of Cas proteins is a viable strategy for improving the performance of one-pot NAAT-CRISPR-Cas assays.